IgA Nephropathy clinical trials at UCSF
2 research studies open to eligible people
IgA nephropathy is a disease where IgA proteins harm the kidneys. At UCSF, researchers are testing BION-1301 to see if it is safe for adults. Another study is investigating whether ravulizumab can decrease protein in the urine and prevent kidney function decline.
Zigakibart in Adults With IgA Nephropathy
open to eligible people ages 18 years and up
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
San Francisco, California and other locations
Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18 years and up
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
San Francisco, California and other locations
Last updated: